The Medical Advisor

Cancer immunotherapy (CIT) has become a standard of care in multiple indications. Apart from radically increasing response rate and prolonging survival, CIT offers the ultimate benefit of any therapy, which is a cure (1). Credit: Statista Since the early days of CIT, it was recognized that the benefit is driven by complicated biological mechanisms, which involves a cross-talk between the tumor, its microenvironment, and the overall immune system of the patient ( 2 ,  3 ). Studies aiming to understand and explore CIT mechanisms of action and pharmacodynamic and response prediction biomarkers have initially evaluated each component independently, but ultimately need to look at these questions in concert. Technological advancements in the field combined with the availability of better translational models and ever-expanding clinical datasets enabled basic, translational, and clinical researchers to have a deeper understanding of this complex interaction ( 4 – 8 ). This combined Resear...